Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in advanced phases of CML, which may permit early allografting for responding patients. To identify prognostic factors in allograft recipients previously treated with IM, we analyzed 449 allogeneic hematopoietic SCTs performed from 1999 to 2004 in advanced-phase CML, using the data reported to the Center for International Blood and Marrow Transplant Research. CML patients in second chronic phase (CP2, n ¼ 184), AP (n ¼ 185) and BP (n ¼ 80) received HLA-identical sibling (27%), related (3%), or matched or mismatched unrelated donor (70%), peripheral blood (47%) or BM (53%) hematopoietic SCT after myeloablative (78%) or non-myeloablative (22%) conditioning. In all, 52% in CP2, 49% in AP and 46% in BP received IM before hematopoietic SCT. Disease-free survival was 35-40% for CP2, 26-27% for AP and 8-11% for BP. Cumulative incidence of acute and chronic GVHD and TRM were not affected by the stages of CML or pre-hematopoietic SCT IM exposure. Multivariate analyses showed that conventional prognostic indicators remain the strongest determinants of transplant outcomes. In conclusion, there are no new prognostic indicators of the outcomes of allogeneic hematopoietic SCT for advanced-phase CML in the IM era.
Introduction
Imatinib mesylate (IM) is a potent and selective inhibitor of the tyrosine kinase activity of BCR-ABL with substantial, albeit transient, activity in advanced-phase CML. Treatment of accelerated (AP) and blast phase (BP) CML with single-agent IM is associated with hematological responses in 50-70%, [1] [2] [3] [4] which is a better result than that achieved with chemotherapy alone. 5 These rapid and high response rates have often allowed patients with a suitable donor to proceed early with allografting. Results of allogeneic hematopoietic SCT in this particular patient population have been reported [6] [7] [8] [9] [10] [11] [12] [13] [14] and have consistently shown a lack of deleterious or beneficial effect of IM on transplant outcomes. However, analyses of prognostic factors were not feasible in these reports, given the relatively small numbers of patients with advanced-phase CML. We therefore sought to analyze the outcomes of allogeneic hematopoietic SCT in advanced-phase CML in the IM era, specifically focusing on prognostic indicators. Approximately, two-thirds of all active transplantation centers worldwide report data to the registry. The registry database includes information on 40-45% of all patients who have received an allotransplant since 1970, with annual updates. Compliance is assessed by periodic audits, and accuracy of data is ensured by computerized record checks, physician review of submitted data and on-site audits. Observational studies conducted by the CIBMTR are done with a waiver of informed consent in compliance with HIPAA (Health Insurance Portability and Accountability Act) regulations, as determined by the Institutional Review Board and Privacy Officer of Medical College of Wisconsin.
Materials and methods

Data source
Patient selection and definitions
The patient population consisted of siblings or unrelated allogeneic hematopoietic cell transplant (HCT) recipients with advanced-phase CML transplanted between 1999 and 2004, as reported to the CIBMTR. A total of 449 cases with CML beyond first chronic phase and complete research data available within the CIBMTR database were identified. Those who received BM or PBSCs from a sibling or from an unrelated donor were selected for analysis. Donorand recipient-HLA matching were defined using the best available HLA-matching data. 15 Patients were conditioned with myeloablative or nonmyeloablative regimens, and received MTX þ calcineurin inhibitor þ /À other drugs for GVHD prophylaxis. The population was restricted to patients with no previous transplantation.
Advanced-phase CML was defined as second chronic phase (CP2), accelerated phase (AP) and blast phase (BP, myeloid or lymphoid or undifferentiated) at the time of hematopoietic SCT. AP was defined on the CIBMTR case report forms by any of the following: anemia (Hb o8 g/ dL), leukocytosis (WBC 4100 Â 10 9 /L), thrombocytopenia (platelets o100 Â 10 9 /L), thrombocytosis (platelets 41000 Â 10 9 /L) or splenomegaly unresponsive to BU or hydroxyurea, extramedullary disease, clonal marrow cytogenetic abnormality(ies) in addition to the original Ph-chromosome, blood or marrow blasts 410%, blood or marrow blasts plus promyelocytes 420% and/or blood basophils þ eosinophils 420%. Patients with more advanced findings were classified as BP. CP2 was defined as return to a second chronic phase or remission after successful treatment of advanced phase. Disease status was captured at the time of diagnosis and immediately before the start of conditioning regimen.
Study-specific supplemental forms were sent to all CIBMTR reporting centers to collect additional information that included the following: time of initiation/stopping of IM, starting dose, maximal dose as well as IM dose reductions, hematological, cytogenetic and molecular responses, toxicity associated with IM, addition of other agents to IM prior to conditioning and reason for transplantation. Data on post-transplant use of IM were also collected. Center responses to these supplemental forms were 68%. Transplant centers providing data on X80% of eligible patients receiving IM during the study period were included.
Study end points
Primary outcomes were overall survival (OS) and leukemiafree survival (LFS, survival in continuous CR). Secondary outcomes included survival at 30 and 100 days, TRM, and grade II-IV acute GVHD and chronic GVHD. Chronic GVHD was assessed in patients surviving more than 90 days with the evidence of engraftment. TRM is defined as death in continued remission; patients were censored at relapse, or, for those in continuous remission, at last follow-up. For LFS, patients were considered to be treatment failures at the time of hematological or cytogenetic relapse or death from any cause; patients alive were censored at the last follow-up evaluation.
Statistical analysis
Multivariate analyses were done using the Cox proportional-hazards regression model with a stepwise selection procedure to identify clinical variables that were associated with particular outcomes. Potential covariates included patient age, sex and race, Karnofsky performance status, time from diagnosis to HCT, donor type, donor-recipient sex match and CMV serological status, HLA matching grade, type of conditioning regimen, graft source, year of transplantation and GVHD prophylaxis. Potential interactions between significant covariates were assessed, and no significant interactions were found to be present. Because of multiple testing, a P-value o0.01 was considered statistically significant. In a separate subgroup analysis, factors associated with survival and TRM were assessed among patients who received pre-hematopoietic SCT-IM. Potential predictors included reason for proceeding to HCT, best response to IM before HCT, duration of IM treatment, and interval between IM discontinuation and HCT, in addition to the other potential clinical predictors listed above. Adequate details about the cytogenetic and molecular burden of disease just before the transplantation were not available. The product-limit estimator proposed by Kaplan-Meier was used to estimate the median and range of the follow-up time. The probabilities of OS and LFS for all patients were calculated using the Kaplan-Meier estimator, with the variance estimated by Greenwood's formula. Patients were censored at the date of lastknown follow-up. Cumulative incidence estimates were calculated for other end points to account for competing risks.
Results
Patients
Between January 1999 and December 2004, 449 patients with CML in AP (n ¼ 185), CP2 (n ¼ 184) and BP (n ¼ 80) at the start of the conditioning regimen met the study eligibility criteria. Pre-transplant IM administration (IM þ ) was reported in 91 AP, 96 CP2 and 37 BP patients. Tables 1 and 2 . Fifty-three patients had a documented history of blast transformation before transplantation, but were in CP2 at the time of conditioning. A total of 41 AP, 41 CP2 and 13 BP patients were prepared for transplantation with a reduced-intensity conditioning regimen. For patients who received IM before transplant, a median daily dose of pre-transplant IM of 600 mg was administered for a median duration of 11 (range 1-54), 7 (range 1-60) and 8 (range 1-36) months in patients with AP, CP2 and BP, respectively. For patients with AP, CP2 and BP, 29%, 52% and 54% were planned for hematopoietic SCT procedures while 62%, 46% and 41% were transplanted for IM failure, respectively. IM was continued up to 4 weeks before transplant in the majority of patients. Information on posttransplant administration of IM was only available in patients who received pre-transplant IM. Of those 214 patients, 56 (25%) received post-transplant IM for relapse prophylaxis (20%), persistent disease (27%), relapsed disease (48%) or for unspecified reasons (5%).
Patient and transplant characteristics are summarized in
Outcomes
Univariate probabilities of day 100 acute GVHD, and 1and 3-year chronic GVHD, TRM, LFS and OS are listed in Table 3 . The Kaplan-Meier plots of OS for patients in AP, BP and CP2 are shown in Figure 1 . Table 4 summarizes the causes of death. Recurrence of the primary disease and GVHD/infection were the most common causes of death in all phases of CML.
Prognostic factors
Cox proportional-hazards regression models were constructed to assess factors that affected OS, LFS, TRM, relapse and acute and chronic GVHD using the variables summarized in the Supplementary Table. Time from diagnosis to transplant, Karnofsky performance status and degree of HLA matching independently predicted OS, relapse and LFS, while GVHD prophylaxis, CMV serostatus, sex mismatch, conditioning regimen and degree of HLA matching affected GVHD and TRM (Table 5 ). Pre- Table 1 Characteristics of CML patients who underwent an allogeneic HSCT for AP, CP2 and BP from 1999 to 2004, and reported to the CIBMTR
Disease status at conditioning
Advanced-phase CML (n ¼ 449) transplant IM had neither a positive nor a negative association with transplant outcomes. A subset analysis in patients who received pre-transplant IM was performed. The duration of pre-transplant IM (dichotomized at 3 and 6 months) did not affect acute or chronic GVHD, TRM, DFS or OS, whereas reason to proceed with transplantation was significantly associated with TRM. Indeed, the relative risk for TRM was 1.8 (95% CI: 1.0-3.4) for patients receiving allograft for IM failure as compared with those with a planned transplant (P ¼ 0.03). In the CP2 group with reported prior BP, patients who received pretransplant IM (n ¼ 23) had a better 1-(61% vs 44%, P ¼ 0.22) and 3-year (41% vs 26%, P ¼ 0.26) survival when compared with those who had no pre-transplant IM (n ¼ 30); however, these differences were not statistically significant. Finally, outcomes of the 95 patients conditioned with reduced intensity were, within each phase of the disease at the time of conditioning, comparable to the 354 patients who received conventional myeloablative conditioning.
Discussion
For patients with CP-CML, treatment with IM is associated with improved survival through higher rates of sustained cytogenetic and molecular remissions, 16 whereas the impact of single-agent IM on outcomes of advancedphase CML, despite high initial responses, is less impressive. Hematopoietic SCT therefore remains an essential part of the therapeutic armamentarium for patients with advanced phases of CML. Several papers have addressed the effects of pre-transplant IM on the outcomes of transplantation, [6] [7] [8] [9] [11] [12] [13] 17 and the safety profile of IM is now well established for all phases of the disease. Addressing prognostic factors in the IM era for advanced-phase CML has been limited by the relatively small number of patients in single-center reports. Additionally, and in particular, outcomes of those patients who respond well to IM and then proceed in remission with allogeneic transplantation are not well defined. The CIBMTR database offers the advantage of a large number of patients with extensive data, which permits performance of multivariate analyses. Our analysis included 449 CML patients with advancedphase CML and confirmed that pre-transplant IM was not associated with deleterious or beneficial effects on post-transplant outcomes. Among the studies that have reported an impact of pre-transplant IM on post-transplant outcomes, three have included historical controls. [6] [7] [8] In a study that included 145IM þ to 231IMÀ allograft recipients with CML, Oehler et al. 6 reported comparable 3-year OS for the 73 advanced-phase IM þ (60 CP2/AP and 13 BP) and the 48 IMÀ (38 CP2/AP and 10 BP) cases. Deininger et al. 8 analyzed 70 CML and 21 Ph þ ALL, and compared the outcomes with historical controls identified in the EBMT database. Pre-transplant IM did not influence OS, progression-free survival or non-relapse mortality, whereas a trend towards higher relapse mortality and significantly less chronic GVHD was observed in the IM þ group (OR ¼ 0.44, P ¼ 0.027). Finally, in 30 Ph chromosome-positive leukemias including 16 advanced-phase CML, outcomes were similar in 48 controls who did not receive prior IM. 7 Previously reported and well-recognized prognostic indicators such as disease phase, age, donor type, donor/ recipient sex mismatch and time from diagnosis to transplant 18, 19 were found, in our analysis, to affect posttransplant outcomes in this patient population. Disappointingly, the outcomes of allografting advanced phase CML remain poor, and have not improved over time and with the availability of IM. Indeed, 35-43% of CP2, 26-37% of AP and 8-16% of BP patients are alive, and are in remission 3 years after transplant. However, CP2 patients defined as remission or chronic phase after prior AP or BP had outcomes comparable to AP and more favorable outcomes than BP patients. Interestingly, comparable survivals were observed after transplantation using a reduced-intensity or myeloablative conditioning. Our results are comparable to outcomes reported by the EBMT on allogeneic transplantation using reduced-intensity conditioning in advanced-phase CML. 20 This study, similar to all registry analyses, has its inherent limitations: it is a retrospective study with a relatively short follow-up (median 3 years). Additionally, requested data from transplant centers were often incompletely reported: 53 and 68% had no information on previous/early BP in the IM þ and IMÀ cohorts. Information on patients identified at conditioning as AP or BP with prior transient remission after treatment with IM was not available. Patients were classified as AP according to the criteria previously defined in the CIBMTR case report forms, and not according to the WHO classification. Although a supplemental data questionnaire was sent to the transplant centers to determine the reasons for which patients proceeded with transplantation (planned, or IM resistance), reasons that often led to delays in transplantation in the IM group were unclear. To circumvent this particular limitation, we analyzed the impact of duration of IM therapy before transplantation on outcomes and no effects were found. Of interest, information on post-transplant use of IM in patients who did not receive pre-transplant IM was not available, and could potentially have affected our results. Finally, data on the presence of BCR/ABL mutations were unavailable. This analysis, in our opinion, is still relevant in 2011. Indeed, and in contrast to chronic-phase CML patients who are more likely to proceed to allogeneic hematopoietic SCT after IM resistance and exposure to second-generation kinase inhibitors, 21, 22 patients presenting at diagnosis with advanced phases of CML usually do so after exposure to front-line IM. This is the approach recommended by the European Leukemia Net 23 and the National Cancer Center Network guidelines (http://www.nccn.org). This study provides an updated outcomes analysis of allografting for these patients. Additionally, one can speculate that with higher remission rates associated with IM as compared with chemotherapy, 5 it is possible, albeit impossible to demonstrate, that a higher fraction of patients reach CP2 after treatment with IM, and therefore are able to undergo transplantation and achieve better outcomes than if they had remained in BP.
In conclusion, in this largest cohort of patients with advanced-phase CML, CP2 and AP patients had similar outcomes, whereas the prognosis of BP patients remained very poor unless CP2 could be achieved. Conventional prognostic indicators remain the major determinants of transplant outcomes in the IM era.
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